Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048870 | 0.86 | PDE2A (0.46) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033609 | 0.85 | PDE2A (0.50) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033866 | 0.84 | PDE2A (0.45) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL4437326 | 0.83 | PDE2A (0.43) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033882 | 0.81 | PDE2A (0.43) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033009 | 0.81 | PDE2A (0.44) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033702 | 0.78 | PDE2A (0.45) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033364 | 0.77 | PDE2A (0.44) | PDE2AIRAK4PDE10APDPK1PRKCZ | |
| SCHEMBL14033865 | 0.76 | PDE2A (0.41) | PDE2APDE10APDPK1PRKCZMARK2 | |
| SCHEMBL14033681 | 0.75 | PDE2A (0.39) | PDE2APDE10APDPK1PRKCZMARK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | PDE2A 2511/4885IRAK4 1203/4885PDE10A 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.